These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9790550)

  • 1. Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer.
    Mitsudomi T; Suzuki S; Yatabe Y; Nishio M; Kuwabara M; Gotoh K; Hatooka S; Shinoda M; Suyama M; Ogawa M; Takahashi T; Ariyoshi Y; Takahashi T
    J Natl Cancer Inst; 1998 Oct; 90(20):1563-8. PubMed ID: 9790550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum anti-p53 antibodies in patients with lung cancer.
    Mack U; Ukena D; Montenarh M; Sybrecht GW
    Oncol Rep; 2000; 7(3):669-74. PubMed ID: 10767388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.
    Iizasa T; Fujisawa T; Saitoh Y; Hiroshima K; Ohwada H
    Cancer Immunol Immunother; 1998 Aug; 46(6):345-9. PubMed ID: 9756419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
    Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
    Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer.
    Laudanski J; Burzykowski T; Niklinska W; Chyczewski K; Furman M; Niklinski J
    Lung Cancer; 1998 Dec; 22(3):191-200. PubMed ID: 10048472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of possible synergistic expression of p53 and p185 as a prognostic tool for stage I non-small-cell lung cancer.
    Cantero R; Torres AJ; Maestro M; Fernández C; Hernando F; del Barco V; Sanz T; Balibrea JL
    World J Surg; 1999 Dec; 23(12):1294-9; discussion 1299-300. PubMed ID: 10552124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer.
    Mitsudomi T; Oyama T; Kusano T; Osaki T; Nakanishi R; Shirakusa T
    J Natl Cancer Inst; 1993 Dec; 85(24):2018-23. PubMed ID: 8246288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer.
    Rosenfeld MR; Malats N; Schramm L; Graus F; Cardenal F; Viñolas N; Rosell R; Torà M; Real FX; Posner JB; Dalmau J
    J Natl Cancer Inst; 1997 Mar; 89(5):381-5. PubMed ID: 9060960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.
    Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T
    Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
    Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
    BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
    Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
    Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
    Huober J; Sprenger H; Costa SD; Zentgraf H; Schmid H; Kaufmann M; Bastert G
    Zentralbl Gynakol; 1996; 118(10):560-4. PubMed ID: 8999710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy.
    Bergqvist M; Brattström D; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Wagenius G; Brodin O
    Anticancer Res; 1998; 18(3B):1999-2002. PubMed ID: 9677456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic relevance of altered pRb and p53 protein expression in surgically treated non-small cell lung cancer patients.
    Dworakowska D; Jassem E; Jassem J; Wiedorn KH; Boltze C; Karmoliński A; Dworakowski R; Skokowski J; Jaśkiewicz K; Bosse A; Czestochowska E
    Oncology; 2004; 67(1):60-6. PubMed ID: 15459497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer.
    Blaes F; Klotz M; Huwer H; Straub U; Kalweit G; Schimrigk K; Schäfers HJ
    Ann Thorac Surg; 2000 Jan; 69(1):254-8. PubMed ID: 10654525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
    Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
    Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The detection of quantitative serum p53 protein in lung cancer.
    Sen E; Gönüllü U; Akar N
    Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.
    Høgdall EV; Høgdall CK; Blaakaer J; Heegaard NH; Glud E; Christensen L; Bock JE; Nørgaard-Pedersen B; Wiik A; Kjaer SK
    APMIS; 2002 Aug; 110(7-8):545-53. PubMed ID: 12390412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serum anti-P53 antibodies (AB-anti-P53) in patients with advanced non-small cell lung cancer (NSCLC)].
    Skrzypski M; Szymanowska A; Janowicz A; Dziadziuszko R; Ramlau R; Kozielski J; Pilarska-Machowicz A; Dobrzańska Z; Bigda J; Krzakowski M; Jassem E; Jassem J
    Pneumonol Alergol Pol; 2002; 70(7-8):353-8. PubMed ID: 12708076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.